| Literature DB >> 36119915 |
Bing Xu1, Ming Liu1, Yonghui Liu1, Jianhong Zuo2.
Abstract
Benign prostatic hyperplasia (BPH) is a common and frequently occurring disease in clinics, with the main manifestations including frequent micturition, urinary incontinence, dysuria, and endless urination. Transurethral resection of the prostate (TURP) is the main treatment for BPH, but some patients are prone to urinary tract infection after surgery, which affects the prognosis. Therefore, it is of great significance to study the pathogenic characteristics and risk factors of postoperative urinary-derived pathogenic bacteria infection in patients with BPH for the prevention and treatment of postoperative infection. In addition, the treatment of patients with this disease is also the focus of clinical attention. Long-term massive application of antibiotics can induce drug-resistant mutations of bacteria, so it is urgent to find an efficient and safe therapeutic scheme in clinics. However, traditional Chinese medicine (TCM) has a long history of treating urinary tract infections. Therefore, Shuangdong capsule, a traditional Chinese medicine preparation, was selected for the combined treatment in this study. The results showed that age, concomitant diabetes mellitus, and preoperative prophylactic application of antibiotics were the independent risk factors for postoperative urine-derived pathogenic infection in BPH patients. Clinical intervention for BPH patients with concomitant risk factors should be emphasized in clinical practice. The combined use of Shuangdong capsule and conventional western medicine can improve the clinical symptoms and inflammatory reactions of postoperative urine-derived pathogenic infection in BPH patients. Due to its exact curative effect and high safety, it is worthy of promotion. The clinical study registration number is M2022019.Entities:
Year: 2022 PMID: 36119915 PMCID: PMC9477594 DOI: 10.1155/2022/4069787
Source DB: PubMed Journal: Emerg Med Int ISSN: 2090-2840 Impact factor: 1.621
Univariate analysis of postoperative urinary pathogenic bacteria infection in patients with BPH.
| Clinical features | Infected group ( | Noninfected group ( |
|
| |
|---|---|---|---|---|---|
| Age (years old) | <60 | 6 (15.00) | 40 (76.92) | 34.677 | <0.001 |
| ≥60 | 34 (85.00) | 12 (23.08) | |||
| BMI (Kg/m2) | <24 | 19 (47.50) | 24 (46.15) | 0.016 | 0.898 |
| ≥24 | 21 (52.50) | 28 (53.85) | |||
| Course of disease (year) | 9.42 ± 2.17 | 9.49 ± 2.19 | 0.154 | 0.879 | |
| IPSS (score) | 24.18 ± 3.95 | 24.56 ± 3.71 | 0.475 | 0.636 | |
| Prostate volume (cm³) | <60 | 5 (12.50) | 41 (78.85) | 39.808 | <0.001 |
| ≥60 | 35 (87.50) | 11 (21.15) | |||
| Concomitant diabetes mellitus | No | 7 (17.50) | 42 (80.77) | 36.356 | <0.001 |
| Yes | 33 (82.50) | 10 (19.23) | |||
| Concomitant hypertension | No | 26 (65.00) | 33 (63.46) | 0.023 | 0.879 |
| Yes | 14 (35.00) | 19 (36.54) | |||
| Concomitant coronary heart disease | No | 25 (62.50) | 30 (57.69) | 0.217 | 0.641 |
| Yes | 15 (37.50) | 22 (42.31) | |||
| Preoperative catheterization | No | 9 (22.50) | 20 (38.46) | 5.655 | 0.017 |
| Yes | 31 (77.50) | 22 (42.31) | |||
| Preoperative prophylactic application of antibiotics | No | 32 (80.00) | 16 (30.77) | 21.960 | <0.001 |
| Yes | 8 (20.00) | 36 (69.23) | |||
| Operation time (min) | <60 | 11 (27.50) | 44 (84.62) | 30.676 | <0.001 |
| ≥60 | 29 (72.50) | 8 (15.38) | |||
| Intraoperative blood loss (ml) | <50 | 8 (20.00) | 39 (75.00) | 1.360 | 0.244 |
| ≥50 | 32 (80.00) | 13 (25.00) | |||
| Postoperative indwelling catheter time ( | <7 | 4 (10.00) | 39 (75.00) | 38.372 | <0.001 |
| ≥7 | 36 (90.00) | 13 (25.00) | |||
Variable assignment of risk factors affecting postoperative urinary pathogenic bacteria infection in BPH patients.
| Variable | Assignment |
|---|---|
| Dependent variable | |
| Infected | 0 = no, 1 = yes |
| Independent variable | |
| Age | 0 = <60 years old, 1 = ≥60 years old |
| Prostate volume | 0 = <60 cm³, 1 = ≥60 cm³ |
| Concomitant diabetes mellitus | 0 = No, 1 = Yes |
| Preoperative catheterization | 0 = No, 1 = Yes |
| Preoperative prophylactic application of antibiotics | 0 = No, 1 = Yes |
| Operation time | 0 = <60 min, 1 = ≥60 min |
| Postoperative indwelling catheter time | 0 = <7 d, 1 = ≥7 d |
Analysis of multiple factors affecting postoperative urinary-derived pathogenic bacteria infection in patients with BPH.
| Variable |
| SE | Wald |
| OR | OR of 95% CI | |
|---|---|---|---|---|---|---|---|
| Upper limit | Lower limit | ||||||
| Age | −3.728 | 1.866 | 3.990 | 0.046 | 0.024 | 0.001 | 0.932 |
| Prostate volume | −4.179 | 2.035 | 4.215 | 0.040 | 0.015 | 0.000 | 0.828 |
| Concomitant diabetes mellitus | −3.188 | 1.580 | 4.073 | 0.044 | 0.041 | 0.002 | 0.912 |
| Preoperative catheterization | −2.172 | 1.596 | 1.853 | 0.173 | 0.114 | 0.005 | 2.599 |
| Preoperative prophylactic application of antibiotics | −4.468 | 1.646 | 7.371 | 0.007 | 0.011 | 0.000 | 0.289 |
| Operation time | −2.733 | 1.586 | 2.971 | 0.085 | 0.065 | 0.003 | 1.454 |
| Postoperative indwelling catheter time | −1.758 | 1.744 | 1.017 | 0.313 | 0.172 | 0.006 | 5.257 |
| Constant | 12.996 | 4.401 | 8.722 | 0.003 | 814.701 | — | — |
Urine-derived pathogenic bacteria infection and distribution in BPH patients after operation.
| Pathogenic bacteria species | Plant number | Constituent ratio (%) | |
|---|---|---|---|
| Gram-negative bacteria |
| 28 | 36.84 |
|
| 15 | 19.74 | |
|
| 12 | 15.79 | |
| Other | 3 | 3.95 | |
| Gram-positive bacteria |
| 13 | 17.11 |
|
| 10 | 13.16 | |
|
| 5 | 6.58 | |
| Other | 1 | 1.32 | |
| Fungi |
| 3 | 3.95 |
| Other | 1 | 1.32 | |
Comparison of clinical effects of patients with different treatment methods.
| Group | Recovery | Marked effective | Effective | Ineffective | Total effective rate (%) |
|---|---|---|---|---|---|
| Research group ( | 16 | 5 | 1 | 1 | 95.00 |
| Control group ( | 8 | 4 | 2 | 6 | 70.00 |
|
| 4.329 | ||||
|
| 0.037 |
Comparison of urinary leukocytes and serum inflammatory factors in patients with different treatment methods before and after treatment ( ± S).
| Group | Urinary leukocyte | TNF- | IL-6 (ng/L) | PCT (pg/L) | ||||
|---|---|---|---|---|---|---|---|---|
| Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
| Research group ( | 90.94 ± 25.83 | 32.15 ± 7.94a | 25.33 ± 4.25 | 16.89 ± 2.91a | 60.24 ± 12.36 | 38.91 ± 6.12a | 159.24 ± 26.12 | 124.24 ± 20.61a |
| Control group ( | 91.06 ± 25.57 | 20.38 ± 7.04a | 25.06 ± 4.14 | 12.04 ± 2.01a | 60.22 ± 12.71 | 29.24 ± 5.12a | 159.32 ± 26.33 | 108.22 ± 21.45a |
|
| 0.015 | 4.960 | 0.204 | 6.134 | 0.005 | 5.420 | 0.010 | 2.408 |
|
| 0.988 | <0.001 | 0.840 | <0.001 | 0.996 | <0.001 | 0.992 | 0.021 |
Note. a P < 0.05, compared with that in the same group before treatment.